COYA Stock Forecast & Price Target

Coya Therapeutics is attractive because its COYA-302 platform targets the underlying Treg dysfunction and chronic inflammation believed to drive ALS and related neurodegenerative disease, with preclinical and clinical evidence showing improved Treg health, reduced inflammatory markers, and encouraging biomarker and safety signals. The company has meaningful near-term catalysts, including ALSTARS enrollment completion in 2H26 and top-line ALS data in 1Q27, plus a new FTD study, while Fast Track designation and a 2040 earliest IP expiry year strengthen the regulatory and strategic profile. Financially, it ended 2Q26 with $43.2M in cash, a net loss of $6.6M, and guidance for runway into 2H27, giving it enough balance-sheet support to reach key readouts and potentially unlock substantial value if clinical efficacy is confirmed.

Coya Therapeutics is viewed negatively because it remains a development-stage biotechnology company with no revenue-generating products and continuing cash burn, leaving it dependent on future debt or equity financing that may be unavailable or substantially dilutive. Its lead programs face meaningful clinical and regulatory risk, including the possibility of failing to achieve statistically significant efficacy, missing FDA or EMA approval, or seeing narrower labels than sought. On top of that, commercialization, reimbursement, intellectual-property, and intense competition from larger, better-capitalized rivals could limit adoption and erode the value of its pipeline.